Currently, POLE2 have reported to be abnormally expressed in breast cancer, colorectal cancer, mantle cell lymphoma, bladder cancer and lung adenocarcinoma (Hartmann et al., 2008; Zhou et al., 2008; Zekri et al., 2015; Chubb et al., 2016; Li et al., 2018). The gene discussed is POLE2; the disease is breast cancer.